These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33984191)

  • 101. Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation.
    Wongcharoen W; Pacharasupa P; Norasetthada L; Gunaparn S; Phrommintikul A
    Circ J; 2020 Jun; 84(7):1075-1082. PubMed ID: 32461505
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery.
    Kok T; de Boer H; Witteman B; Hovens M; van Luin M; Monajemi H
    Obes Surg; 2022 Mar; 32(3):607-614. PubMed ID: 34822108
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Patient-reported outcomes and apixaban therapy in older patients.
    Fumagalli S; Di Pasquale G; Pupo S; Agnelli G; Marchionni N;
    Eur J Intern Med; 2024 Jun; 124():156-159. PubMed ID: 38472046
    [No Abstract]   [Full Text] [Related]  

  • 104. The effect of contrast agents on the anticoagulant properties of oral factor Xa inhibitors.
    Cavlan B; Ari S; Ari H; Çamci S; Melek M; Bozat T
    Acta Radiol; 2023 Feb; 64(2):588-595. PubMed ID: 35296141
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Critical Analysis of Apixaban Dose Adjustment Criteria.
    Vu A; Qu TT; Ryu R; Nandkeolyar S; Jacobson A; Hong LT
    Clin Appl Thromb Hemost; 2021; 27():10760296211021158. PubMed ID: 34075813
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Apixaban to Prevent Recurrence After Cryptogenic Stroke.
    Rigatelli G; Zuin M
    JAMA; 2024 Jun; 331(22):1966. PubMed ID: 38739405
    [No Abstract]   [Full Text] [Related]  

  • 107. Apixaban to Prevent Recurrence After Cryptogenic Stroke.
    Chi KY; Nanna M; Nanna MG
    JAMA; 2024 Jun; 331(22):1965-1966. PubMed ID: 38739398
    [No Abstract]   [Full Text] [Related]  

  • 108. Apixaban to Prevent Recurrence After Cryptogenic Stroke.
    Wen X; Yan J; Zhu Z
    JAMA; 2024 Jun; 331(22):1966. PubMed ID: 38739376
    [No Abstract]   [Full Text] [Related]  

  • 109. Apixaban to Prevent Recurrence After Cryptogenic Stroke-Reply.
    Kamel H; Tirschwell DL; Elkind MSV;
    JAMA; 2024 Jun; 331(22):1966-1967. PubMed ID: 38739409
    [No Abstract]   [Full Text] [Related]  

  • 110. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.
    López-Gálvez R; Rivera-Caravaca JM; Anguita Sánchez M; Sanmartín Fernández M; Rafols C; Pérez-Cabeza AI; Barón Esquivias G; Lekuona Goya I; Vázquez Rodríguez JM; Cosín Sales J; Arribas Ynsaurriaga F; Barrios V; Freixa-Pamias R; Marín F
    Eur J Clin Invest; 2022 Sep; 52(9):e13788. PubMed ID: 35395094
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia.
    Dix C; McFadyen JD; Tran HA
    Thromb Res; 2024 May; 237():148-153. PubMed ID: 38603817
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Effects of Atorvastatin on Serum High-Sensitive C-Reactive Protein and Total Cholesterol Levels in Asian Patients With Atrial Fibrillation.
    Wang J; Wang AR; Zhang MJ; Li Y
    Am J Ther; 2017; 24(1):e20-e29. PubMed ID: 26566148
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Calibration and validation of the rabbit model of electrolytic-mediated arterial thrombosis against the standard-of-care anticoagulant apixaban.
    Wong PC; Crain E
    Pharmacol Res Perspect; 2022 Jun; 10(3):e00963. PubMed ID: 35680619
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Gender-Associated Variation in DOAC Levels.
    Moldenhauer A; Hellstern P; Hoffmann T; Fischer JC
    Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436398
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Effect of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of rivaroxaban and edoxaban in patients with nonvalvular atrial fibrillation.
    Nakagawa J; Kinjo T; Aiuchi N; Ueno K; Tomita H; Niioka T
    Eur J Clin Pharmacol; 2023 May; 79(5):703-705. PubMed ID: 36951964
    [No Abstract]   [Full Text] [Related]  

  • 116. Stability of Rivaroxaban and Apixaban Anti-Xa Activities in Whole Blood Samples: A French Bicentric Study.
    Raynor A; Lunte K; Gaaloul M; Caillault A; Zouiti F; Desconclois C; Planche V
    Thromb Haemost; 2023 May; 123(5):565-567. PubMed ID: 36791800
    [No Abstract]   [Full Text] [Related]  

  • 117. Apixaban and Rivaroxaban Anti-Xa Concentration Utilization in Clinical Practice.
    Kim JH; Shelat N; Ji CS
    J Cardiovasc Pharmacol; 2023 Feb; 81(2):165-170. PubMed ID: 36607730
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes.
    Wang Z; Zhu LY; Yu LY; Chen WQ; Chen YN; Li Q; Liu Y; Jiao SQ; Zhai ZG; Zhao L; Sun YH
    Thromb Res; 2022 Oct; 218():189-191. PubMed ID: 36087354
    [No Abstract]   [Full Text] [Related]  

  • 119. Observed Apixaban Anti-Xa Levels in Obese Patients.
    Harkness W; Pipitone O; Joss J; Schiedler M; Shagavah S; Moore R; Hsing J
    Ann Pharmacother; 2022 Feb; ():10600280221077158. PubMed ID: 35168381
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Apixaban plasma concentrations in patients with obesity.
    Al-Aieshy F; Skeppholm M; Fyrestam J; Johansson F; Pohanka A; Malmström RE
    Eur J Clin Pharmacol; 2024 Sep; 80(9):1343-1354. PubMed ID: 38822847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.